➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
Colorcon
Baxter
Dow
Mallinckrodt

Last Updated: June 25, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Ularitide


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Ularitide?

Ularitide is an investigational drug.

There have been 5 clinical trials for Ularitide. The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2020.

The most common disease conditions in clinical trials are Heart Failure, Liver Cirrhosis, and Fibrosis. The leading clinical trial sponsors are Vanderbilt University Medical Center, AstraZeneca, and Cardiorentis.

There are two hundred and twenty US patents protecting this investigational drug and two international patents.

Recent Clinical Trials for Ularitide
TitleSponsorPhase
Refractory Ascites in Patients With Liver Cirrhosis, and the Potential Treatment With 48 Hours Infusion of Ularitide.Aarhus University HospitalPhase 2
Refractory Ascites in Patients With Liver Cirrhosis, and the Potential Treatment With 48 Hours Infusion of Ularitide.ADS AIPHIA Development Services AGPhase 2
Refractory Ascites in Patients With Liver Cirrhosis, and the Potential Treatment With 48 Hours Infusion of Ularitide.University of AarhusPhase 2

See all Ularitide clinical trials

Clinical Trial Summary for Ularitide

Top disease conditions for Ularitide
Top clinical trial sponsors for Ularitide

See all Ularitide clinical trials

US Patents for Ularitide

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ularitide   Get Started Free ANP fragment adjuvant therapy to standard of care (SOC) diuretic treatment Madeleine Pharmaceuticals Pty Ltd. (Mount Barker, AU)   Get Started Free
Ularitide   Get Started Free Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA)   Get Started Free
Ularitide   Get Started Free Peptide pharmaceuticals EUMEDERIS PHARMACEUTICALS, INC. (San Diego, CA)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ularitide

Drugname Country Document Number Estimated Expiration Related US Patent
Ularitide Australia AU2015230666 2034-04-09   Get Started Free
Ularitide Australia AU2015230778 2034-04-09   Get Started Free
Ularitide European Patent Office EP2968458 2033-03-15   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Dow
Baxter
Mallinckrodt
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.